Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa

Phase 3

Completed

• Conditions: Acute Otitis Externa
• Interventions: Drug: AL-60371, 0.3% otic suspension; Drug: AL-60371 Vehicle

• Registration Number: NCT01535560
• Lead Sponsor: Alcon Research

Brief Summary

The purpose of this study was to demonstrate superiority of AL-60371 relative to Vehicle based on clinical cures at test-of-cure (TOC) for the treatment of acute otitis externa (AOE).

Detailed Description

Participants or legal guardians completed a telephone diary twice daily to record assessments of ear pain, ear medication use, and impact of ear pain on sleep and other daily activities.

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study First Submitted: 2012-02-15
• Study First Submitted QC: 2012-02-15
• Study First Posted: 2012-02-17
• Study Start: 2012-04
• Primary Completion: 2012-10
• Study Completion: 2012-10
• Status Verified: 2013-10
• Results First Submitted: 2013-10-18
• Results First Submitted QC: 2013-10-18
• Last Update Submitted: 2013-10-18
• Results First Posted: 2013-12-10
• Last Update Posted: 2013-12-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 589

Inclusion Criteria

• At least 6 months of age.
• Clinical diagnosis of acute otitis externa (AOE) based on clinical observation and of presumed bacterial origin in at least one ear.
• Combined numerical score of ≥4 in at least one affected ear at the Day 1 exam for tenderness, erythema, and edema.
• Agree to refrain from water immersion of the ears during the conduct of the entire study.
• Other protocol-defined inclusion criteria may apply.

Read More

Exclusion Criteria

• Duration of signs or symptoms of AOE greater than 28 days in the affected ear(s) as reported by patient or parent/guardian.
• Presence of a tympanostomy tube or perforated tympanic membrane in the affected ear(s).
• Clinically diagnosed otic disease other than AOE (eg, malignant otitis externa) in the affected ear(s).
• Known or suspected ear infection of yeast, fungal or mycobacterial origin in the affected ear(s).
• Prior otologic surgery within 6 months of study entry in the affected ear(s).
• Known or suspected allergy or hypersensitivity to quinolones or other ingredients present in the medications to be used in the study.
• Patients who use ear plugs, head phones or ear buds and are unwilling to discontinue their use during the study period.
• Other protocol-defined exclusion criteria may apply.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
AL-60371	AL-60371, 0.3% otic suspension	AL-60371, 0.3% otic suspension, 4 drops in the affected ear(s) twice daily for 7 days
Vehicle	AL-60371 Vehicle	AL-60371 Vehicle, 4 drops in the affected ear(s) twice daily for 7 days

Primary Outcome Measures

Name	Time	Method
Proportion of Patients With Clinical Cures at the Day 11 (TOC) Visit	Day 11	An otoscopic exam was conducted by the physician. Clinical cure was considered attained if the sum of the numerical scores of the 3 signs and symptoms of AOE (tenderness, erythema, and edema) was 0 at Day 11. Proportion of patients is reported as percentage of participants.

Secondary Outcome Measures

Name	Time	Method
Proportion of Patients With Microbiological Successes at the Day 11 (TOC) Visit	Day 11	Microbiological success was considered attained if all pre-therapy bacteria were absent from the exit otic specimen. The presence of fungi and/or yeast was not considered in the determination of microbiological success. Proportion of patients is reported as a percentage of participants.
Median Time (in Days) to Cessation of Ear Pain as Reported by the Patient or Parent/Legal Guadian Via the Telephone Diary	Time to event (Day 1 to Day 11)	Cessation of ear pain was defined as occurring the first time point that ear pain was absent (morning or evening) and did not reoccur in any subsequent diary entries.